Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis

被引：3

作者：

Harrison, Simon J. ^{[1
]}

Richardson, Paul G. ^{[2
]}

Alegre, Adrian ^{[3
]}

Simpson, David ^{[4
]}

Wang, Ming Chung ^{[5
]}

Spencer, Andrew ^{[6
]}

Delimpasi, Sossana ^{[7
]}

Hulin, Cyrille ^{[8
]}

Sunami, Kazutaka ^{[9
]}

Facon, Thierry ^{[10
]}

Vlummens, Philip ^{[11
]}

Yong, Kwee ^{[12
]}

Campana, Frank ^{[13
]}

Inchauspe, Marlene ^{[14
]}

Mace, Sandrine ^{[15
]}

Risse, Marie-Laure ^{[16
]}

van de Velde, Helgi ^{[17
]}

Attal, Michel ^{[18
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Harvard Med Sch, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[3] Univ Hosp La Princesa, Madrid, Spain

[4] North Shore Hosp, Auckland, New Zealand

[5] Chang Gung Med Fdn, Taipei, Taiwan

[6] Monash Univ, Australian Ctr Blood Dis, Alfred Hosp, Melbourne, Vic, Australia

[7] Evangelismos Med Ctr, Athens, Greece

[8] CHU Bordeaux, Hop Haut Leveque, Serv Hematol, Bordeaux, France

[9] Natl Hosp Org Okayama Med Ctr, Dept Hematol, Okayama, Japan

[10] Lille Univ Hosp, Dept Haematol, Lille, France

[11] Univ Ghent, Dept Haematol, Ghent, Belgium

[12] Univ Coll Hosp, Dept Haematol, London, England

[13] Sanofi Genzyme Oncol, Cambridge, MA USA

[14] Sanofi R&D, Vitry Sur Seine, France

[15] Sanofi R&D, Sanofi, Vitry Sur Seine, France

[16] Sanofi R&D, Vitry Alfortville, France

[17] Sanofi, Cambridge, MA USA

[18] Inst Natl Sante, Univ Canc Ctr Toulouse, Toulouse, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

CD38; High-risk cytogenetics; Multiple myeloma;

D O I：

10.1016/j.clml.2019.09.049

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-048

引用

页码：E33 / E33

页数：1